

20a-t) Publicações relativas ao composto LASSBio-294:

- 20a JR Azevedo, J-J Letourneau, F Espitalier, MI Ré, Solubility of a new cardioactive prototype drug in ionic liquids, *J. Chem. Eng. Data*, **59**, 1766–1773 (2014). Doi: 10.1021/je4009624 [[CrossRef](#)];
- b) JS da Silva, SL Pereira, RC Maia, SS Landgraf, C Caruso-Neves, AE Kümmerle, CAM Fraga, EJ Barreiro, RT Sudo, G Zapata-Sudo, *N*-acylhydrazone improves exercise intolerance in rats submitted to myocardial infarction by the recovery of calcium homeostasis in skeletal muscle, *Life Sciences*, **94**, 30–36 (2014). Doi: 10.1016/j.lfs.2013.11.012 [[CrossRef](#)];
- c) FN Costa, FF Ferreira, TF da Silva, EJ Barreiro, LM Lima, D Braza, RC Barroso, Structure re-determination of LASSBio-294 – a cardioactive compound of the *N*-acylhydrazone class – using X-ray powder diffraction data, *Powder Diffraction*, **28**, S491-S509 (2013). Doi: 10.1017/S0885715613000808 [[CrossRef](#)];
- d) ACB Torres, PR Nasciutti, IP Bittar, RV Muniz, TM Guimarães, V Oliveira, AB Fraga, RO Alves, Pharmacological profile of the cardioactive prototypes LASSBio-294 and LASSBio-897: A comparative preliminary study of their metabolites' effects on myocardial contraction, *J. Vet. Intern. Med.*, **27**, 647-647 (2013). [[CrossRef](#)];
- e) CM Leal, SL Pereira, AE Kümmerle, DM Leal, R Tesch, CMR Sant'Anna, CAM Fraga, EJ Barreiro, RT Sudo, G Zapata-Sudo, Antihypertensive profile of 2-thienyl-3,4-methylenedioxybenzoylhydrazone is mediated by activation of the A_{2A} adenosine receptor, *Eur. J. Med. Chem.*, **55**, 49–57 (2012). Doi: 10.1016/j.ejmech.2012.06.056 [[CrossRef](#)];
- f) RC Braga, VM Alves, CAM Fraga, EJ Barreiro, V de Oliveira, CH Andrade, Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone, *J. Mol. Model.*, **18**, 2065–2078 (2012). Doi: 10.1007/s00894-011-1219-9 [[CrossRef](#)];
- g) RC Braga, ACB Tôrres, CB Persiano, RO Alves, CAM Fraga, EJ Barreiro, V de Oliveira, Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LC–MS/MS: Application for a pharmacokinetic study, *Journal of Pharmaceutical and Biomedical Analysis*, **55**, 1024-1030 (2011). Doi: 10.1016/j.jpba.2011.02.031 [[CrossRef](#)];
- h) A G M Fraga, L L da Silva, CAM Fraga, EJ Barreiro, CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes and human recombinant CYP enzymes, *Eur. J. Med. Chem.*, **46**, 349-355 (2011). Doi: 10.1016/j.ejmech.2010.11.024 [[CrossRef](#)];
- j) DG Costa, JS da Silva, AE Kummerle et al., LASSBio-294, A compound with inotropic and lusitropic activity, decreases cardiac remodeling and improves Ca²⁺ influx into sarcoplasmic reticulum after myocardial infarction, *Am. J. Hypertension*, **23**, 1220-1227 (2010). Doi: 10.1038/ajh.2010.157 [[CrossRef](#)];
- j) FCF Brito, AE Kummerle, C Lugnier et al., Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A₂ synthesis inhibition, *Eur. J. Pharmacol.*, **638**, 5-12 (2010). Doi: 10.1016/j.ejphar.2010.04.003 [[CrossRef](#)];
- k) EO Carneiro, CH Andrade, RC Braga et al., Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294, *Bioorg. Med. Chem. Lett.*, **20**, 3734-3736 (2010). Doi: 10.1016/j.bmcl.2010.04.073 [[CrossRef](#)];
- l) L Pol-Fachin, CAM Fraga, EJ Barreiro et al., Characterization of the conformational ensemble from bioactive *N*-acylhydrazone derivatives, *J. Mol. Graphics & Modelling*, **28**, 446-454 (2010). Doi: 10.1016/j.jmgm.2009.10.004 [[CrossRef](#)];
- m) AE Kummerle, JM Raimundo, CM Leal et al., Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene *N*-acylhydrazone derivatives, *Eur. J. Med. Chem.*, **44**, 4004-4009 (2009). Doi: 10.1016/j.ejmech.2009.04.044 [[CrossRef](#)];

- n) AG Silva, G Zapata-Sudo, AE Kummerle *et al.*, Synthesis and vasodilatory activity of new *N*-acylhydrazone derivatives, designed as LASSBio-294 analogues, *Bioorg. Med. Chem.*, **13**, 3431-3437 (2005). Doi: 10.1016/j.bmc.2005.03.003 [[CrossRef](#)];
- o) G Zapata-Sudo, RT Sudo, PA Maronas *et al.*, Thienylhydrazone derivative increases sarcoplasmic reticulum Ca²⁺ release in mammalian skeletal muscle, *Eur. J. Pharmacol.*, **470**, 79-85 (2003). Doi: 10.1016/S0014-2999(03)01757-6 [[CrossRef](#)];
- p) EJ Barreiro, Strategy of molecular simplification in rational drug design: The discovery of a new cardioactive agent, *Quim. Nova*, **25**, 1172-1180 (2002). Doi: 10.1590/S0100-40422002000700018 [[CrossRef](#)];
- q) CLM Silva, F Noel, EJ Barreiro, Cyclic GMP-dependent vasodilatory properties of LASSBio 294 in rat aorta, *Br. J. Pharmacol.*, **135**, 293-298 (2002). Doi: 10.1038/sj.bjp.0704473 [[CrossRef](#)];
- r) H Gonzalez-Serratos, RZ Chang, EFR Pereira *et al.*, A novel thienylhydrazone, (2-thienylidene)3,4-methylenedioxybenzoylhydrazine, increases inotropism and decreases fatigue of skeletal muscle, *J. Pharmacol. Exp. Ther.*, **299**, 558-566 (2001). [[CrossRef](#)];
- s) RT Sudo, G Zapata-Sudo, EJ Barreiro, The new compound, LASSBio 294, increases the contractility of intact and saponin-skinned cardiac muscle from Wistar rats, *Br. J. Pharmacol.*, **134**, 603-613 (2001) Doi: 10.1038/sj.bjp.0704291 [[CrossRef](#)];
- t) PC Lima, LM Lima, KCM Silva *et al.*, Synthesis and analgesic activity of novel *N*-acylarylhydrazones and isosters, derived from natural safrole, *Eur. J. Med. Chem.*, **35**, 187-203 (2000). Doi: 10.1016/S0223-5234(00)00120-3 [[CrossRef](#)]